Voyager Therapeutics
VYGR
111 hedge funds and large institutions have $526M invested in Voyager Therapeutics in 2019 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 44 increasing their positions, 33 reducing their positions, and 22 closing their positions.
397% more call options, than puts
Call options by funds: $1.54M | Put options by funds: $309K
101% more capital invested
Capital invested by funds: $262M → $526M (+$264M)
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
33% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 33
1.28% less ownership
Funds ownership: 85.56% → 84.28% (-1.3%)
4% less funds holding
Funds holding: 116 → 111 (-5)
23% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 22
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$25.4M |
| 2 |
ClearBridge Investments
New York
|
+$4.94M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
+$4.04M |
| 4 |
EAM
Erste Asset Management
Vienna,
Austria
|
+$3.13M |
| 5 |
D.E. Shaw & Co
New York
|
+$2.62M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$16.9M |
| 2 |
HCM
Highline Capital Management
New York
|
-$9.06M |
| 3 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$4.1M |
| 4 |
Millennium Management
New York
|
-$3.44M |
| 5 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$3.43M |
VYGR Hedge Fund Activity: Q1 2019 in Review
111 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Voyager Therapeutics (VYGR) for Q1 2019, worth a combined $526M — up 101% from $262M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of VYGR and 17 opened new positions — a net loss of 5 holders — while 33 trimmed existing stakes and 44 added.
The largest buyer was PFM Health Sciences, opening a new position worth an estimated $25.4M. The largest seller was Armistice Capital, cutting an estimated $16.9M.
- 111 institutional investors held Voyager Therapeutics (VYGR) as of Q1 2019, down from 116 in Q4 2018.
- Funds reported $526M of Voyager Therapeutics stock for Q1 2019, up 101% quarter-over-quarter.
- 17 funds opened new Voyager Therapeutics positions in Q1 2019 and 22 closed out, a net change of -5 holders.
- The largest Voyager Therapeutics buyer in Q1 2019 was PFM Health Sciences, an estimated $25.4M added.
- The largest Voyager Therapeutics seller in Q1 2019 was Armistice Capital, an estimated $16.9M sold.
Based on aggregated 13F filings for Q1 2019.